Direct targeting of MCL-1 or BCL-XL can restore the apoptotic threshold, but first-generation agents revealed safety ceilings: BCL-XL inhibitors (e.g., navitoclax) cause dose-limiting thrombocytopenia, and MCL-1 inhibitors show cardiac toxicity with continuous dosing (Roberts et al., 2021). This evidence concerns the gene BCL2L1 and Thrombocytopenia.